Prolactin News and Research

RSS

UW-Madison scientists discover bone marrow proteins that regulate bone-building cells

The prospect of regenerating bone lost to cancer or trauma is a step closer to the clinic as University of Wisconsin-Madison scientists have identified two proteins found in bone marrow as key regulators of the master cells responsible for making new bone.

2 Feb 2017

Screening for prolactin receptor could help improve TNBC prognosis and treatment

A study conducted at the Research Institute of the McGill University Health Centre suggests screening breast cancer patients for the prolactin receptor could improve the prognosis for patient and may help them avoid unnecessary and invasive treatments

24 Oct 2016

Yale scientists provide new insights into evolutionary origin of female orgasm

Female orgasm seems to be a happy afterthought of our evolutionary past when it helped stimulate ovulation, a new study of mammals shows.

1 Aug 2016

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan plc today announced that SAPHRIS (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17).

17 Jul 2015

Hormones used in breast cancer treatment could affect disease progression, outcomes in some patients

Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy.

22 Jun 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Hormone that stimulates milk production in nursing mothers also fosters bond between parents

Research has discovered a role for prolactin, the hormone that stimulates milk production in nursing mothers, in the bond between parents.

31 Mar 2015

Childhood macroprolactinomas amenable to dopamine agonist treatment

Dopamine agonist treatment normalises prolactin levels in about three-quarters of children with macroprolactinomas, show findings from a large series.

30 Jan 2015

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults.

19 Nov 2014

Mylan releases generic version of Zyprexa Zydis Tablets

Mylan Inc. today announced that it has launched Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of Eli Lilly and Company's Zyprexa Zydis Tablets.

14 May 2014

Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research

Under stress from chemotherapy or radiation, some cancer cells dodge death by consuming a bit of themselves, allowing them to essentially sleep through treatment and later awaken as tougher, resistant disease.

4 Apr 2014

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Exposure to multiple estrogen-mimicking chemicals distorts hormone action

For years, scientists have been concerned about chemicals in the environment that mimic the estrogens found in the body. In study after study, researchers have found links between these "xenoestrogens" and such problems as decreased sperm viability, ovarian dysfunction, neurodevelopmental deficits and obesity.

29 Mar 2013

Very low levels of BPS can disrupt natural estrogen hormone actions

A few years ago, manufacturers of water bottles, food containers, and baby products had a big problem. A key ingredient of the plastics they used to make their merchandise, an organic compound called bisphenol A, had been linked by scientists to diabetes, asthma and cancer and altered prostate and neurological development.

23 Jan 2013

BMI influences hormone levels in overweight, obesity

A high body mass index has no significant impact on parameters of sperm quality, although it does lower serum levels of testosterone, luteinizing hormone, and prolactin, say researchers.

5 Dec 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Study explains link between infertility and hyperprolactinaemia

One of the most frequent is the existence of tumours that induce an over-secretion of this hormone. These women present with chronic infertility due to anovulation. Thanks to the work of the Inserm researchers from unit 693 "Steroid receptors: endocrinian and metabolic physiopathology", the intimate mechanism of the hyperprolactinaemia alterations affecting reproduction in mice has been discovered.

19 Oct 2012

Kisspeptin reverses hyperprolactinemia-induced ovarian acyclicity

Kisspeptin neurons appear to play a role in hypogonadotropic anovulation caused by excessive levels of prolactin, research shows.

1 Oct 2012